MX2015012783A - Administracion subcutanea de una desintegrina y metaloproteinasa con motivos tipo i de trombospondina 13 (adamts13). - Google Patents

Administracion subcutanea de una desintegrina y metaloproteinasa con motivos tipo i de trombospondina 13 (adamts13).

Info

Publication number
MX2015012783A
MX2015012783A MX2015012783A MX2015012783A MX2015012783A MX 2015012783 A MX2015012783 A MX 2015012783A MX 2015012783 A MX2015012783 A MX 2015012783A MX 2015012783 A MX2015012783 A MX 2015012783A MX 2015012783 A MX2015012783 A MX 2015012783A
Authority
MX
Mexico
Prior art keywords
adamts13
subcutaneous administration
evidence
treat
disease
Prior art date
Application number
MX2015012783A
Other languages
English (en)
Inventor
Hanspeter Rottensteiner
Alexandra Nathalie Schiviz
Werner Hoellriegl
Barbara Plaimauer
Eva-Maria Muchitsch
Original Assignee
Baxalta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta Inc filed Critical Baxalta Inc
Publication of MX2015012783A publication Critical patent/MX2015012783A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24087—ADAMTS13 endopeptidase (3.4.24.87)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La presente invención se relaciona con métodos de administración subcutánea de formulaciones de ADAMTS13 para tratar una enfermedad o afección asociada a la disfunción de vWF y ADAMTS13. Además, en la presente se proporcionan pruebas de la alta biodisponibilidad no esperada de las formulaciones de ADAMTS13 administradas por vía subcutánea.
MX2015012783A 2013-03-15 2014-03-13 Administracion subcutanea de una desintegrina y metaloproteinasa con motivos tipo i de trombospondina 13 (adamts13). MX2015012783A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361794659P 2013-03-15 2013-03-15
PCT/US2014/026747 WO2014151968A1 (en) 2013-03-15 2014-03-13 Subcutaneous administration of adamts13

Publications (1)

Publication Number Publication Date
MX2015012783A true MX2015012783A (es) 2016-04-28

Family

ID=50549463

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015012783A MX2015012783A (es) 2013-03-15 2014-03-13 Administracion subcutanea de una desintegrina y metaloproteinasa con motivos tipo i de trombospondina 13 (adamts13).
MX2021002513A MX2021002513A (es) 2013-03-15 2015-09-14 Composicion que comprende desintegrina y metaloproteinasa con motivos tipo i de trombospondina 13 (adamts13) para administracion subcutanea.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021002513A MX2021002513A (es) 2013-03-15 2015-09-14 Composicion que comprende desintegrina y metaloproteinasa con motivos tipo i de trombospondina 13 (adamts13) para administracion subcutanea.

Country Status (19)

Country Link
US (4) US9611467B2 (es)
EP (2) EP3960196A1 (es)
JP (4) JP6484216B2 (es)
KR (5) KR102513872B1 (es)
CN (2) CN114259558A (es)
AU (5) AU2013203062C1 (es)
BR (1) BR112015023542A8 (es)
CA (1) CA2905058A1 (es)
DK (1) DK2968483T3 (es)
EA (2) EA034546B1 (es)
ES (1) ES2906550T3 (es)
HK (1) HK1220131A1 (es)
IL (3) IL241305B (es)
MX (2) MX2015012783A (es)
PL (1) PL2968483T3 (es)
PT (1) PT2968483T (es)
SG (3) SG10202001227QA (es)
TW (4) TWI740207B (es)
WO (1) WO2014151968A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013203062C1 (en) 2013-03-15 2018-06-28 Takeda Pharmaceutical Company Limited Subcutaneous administration of adamts13
GB201510870D0 (en) * 2015-05-26 2015-08-05 Baxalta Inc And Katholieke Universiteit Leuven And Baxalta Gmbh Treatment of infarction
EA201990373A1 (ru) 2016-08-04 2019-07-31 Баксалта Инкорпорэйтед Применение adamts13 для лечения, уменьшения интенсивности и/или предупреждения вазоокклюзивного криза при серповидноклеточной анемии, остром повреждении легкого и/или остром респираторном дистресс-синдроме
WO2020214033A1 (en) * 2019-04-17 2020-10-22 Erasmus University Medical Center Rotterdam Papain-like cysteine peptidase medicaments and uses thereof
CA3173709A1 (en) 2020-04-02 2021-10-07 Friedmund BACHMANN Adamts13 variant, compositions, and uses thereof
US20230201319A1 (en) 2020-05-22 2023-06-29 Takeda Pharmaceutical Company Limited Adamts13 compositions and methods for treating and diagnosing complications of coronavirus disease
KR20220068144A (ko) * 2020-11-18 2022-05-25 주식회사 녹십자 자가 항체에 대한 회피율 또는 활성이 증가된 adamts13 변이체
GB202102208D0 (en) * 2021-02-17 2021-03-31 Univ Manchester Adamts13 variant

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL113010A (en) 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
US6926894B2 (en) 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
US7037658B2 (en) 2001-08-16 2006-05-02 Regents Of University Of Michigan Methods and compositions for detecting variant ADAMTS13 genes
US7763430B2 (en) 2003-04-22 2010-07-27 Baxter International Inc. Diagnostic assay for anti-von Willebrand Factor cleaving protease (ADAMTS13) antibodies
AU2006257073B2 (en) * 2005-06-17 2011-08-04 Children's Medical Center Corporation ADAMTS13-comprising compositions having thrombolytic activity
JP2009539757A (ja) * 2006-06-16 2009-11-19 バクスター・インターナショナル・インコーポレイテッド 血栓溶解活性を有するａｄａｍｔｓ１３含有組成物
WO2009140140A1 (en) 2008-05-12 2009-11-19 Immune Disease Institute Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
US20120148557A1 (en) * 2009-08-20 2012-06-14 Ulrich Kronthaler Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
KR20210054598A (ko) * 2009-09-21 2021-05-13 다케다 야쿠힌 고교 가부시키가이샤 안정화된 액체 및 동결건조된 ａｄａｍｔｓ13 제제
BR112013000515B1 (pt) * 2010-07-08 2021-11-03 Takeda Pharmaceutical Company Limited Método para produzir uma composição de fator von willebrand recombinante (rvwf)
AU2013203062C1 (en) 2013-03-15 2018-06-28 Takeda Pharmaceutical Company Limited Subcutaneous administration of adamts13

Also Published As

Publication number Publication date
IL241305A0 (en) 2015-11-30
NZ712440A (en) 2020-11-27
TW202313664A (zh) 2023-04-01
PL2968483T3 (pl) 2022-04-04
SG10201707074TA (en) 2017-10-30
NZ749570A (en) 2020-11-27
US10413600B2 (en) 2019-09-17
KR102218489B1 (ko) 2021-02-22
BR112015023542A2 (pt) 2017-07-18
US20140271611A1 (en) 2014-09-18
TW202017591A (zh) 2020-05-16
WO2014151968A8 (en) 2015-10-15
BR112015023542A8 (pt) 2019-12-03
AU2013203062C1 (en) 2018-06-28
EA201591758A1 (ru) 2016-03-31
IL290486A (en) 2022-04-01
KR102513872B1 (ko) 2023-03-27
KR20210021107A (ko) 2021-02-24
AU2016231547B2 (en) 2018-03-15
ES2906550T3 (es) 2022-04-19
US11779635B2 (en) 2023-10-10
EA034546B1 (ru) 2020-02-19
EP2968483B1 (en) 2021-12-01
MX2021002513A (es) 2021-04-28
IL273365B (en) 2022-05-01
SG11201507271QA (en) 2015-10-29
TWI786563B (zh) 2022-12-11
AU2020202738B2 (en) 2022-06-09
AU2022211908A1 (en) 2022-09-01
IL290486B1 (en) 2023-04-01
HK1220131A1 (zh) 2017-04-28
DK2968483T3 (da) 2022-02-14
JP2019142850A (ja) 2019-08-29
TWI690326B (zh) 2020-04-11
EA201992832A1 (ru) 2020-05-31
AU2018203665B2 (en) 2020-01-30
KR20190022926A (ko) 2019-03-06
IL273365A (en) 2020-05-31
AU2020202738A1 (en) 2020-05-14
AU2013203062A1 (en) 2014-10-02
US20220080032A1 (en) 2022-03-17
US20200101144A1 (en) 2020-04-02
KR102365936B1 (ko) 2022-02-23
AU2016231547A1 (en) 2016-10-06
AU2022211908B2 (en) 2023-11-30
CN105407912A (zh) 2016-03-16
KR20220027266A (ko) 2022-03-07
TW202138003A (zh) 2021-10-16
KR102102087B1 (ko) 2020-04-20
KR20160016756A (ko) 2016-02-15
EA201591758A8 (ru) 2017-03-31
TW201513881A (zh) 2015-04-16
US20170224785A1 (en) 2017-08-10
IL290486B2 (en) 2023-08-01
JP6484216B2 (ja) 2019-03-13
PT2968483T (pt) 2022-02-23
JP6998333B2 (ja) 2022-02-10
WO2014151968A1 (en) 2014-09-25
EP2968483A1 (en) 2016-01-20
JP7238088B2 (ja) 2023-03-13
CN114259558A (zh) 2022-04-01
AU2013203062B2 (en) 2016-06-23
JP2022027991A (ja) 2022-02-14
IL241305B (en) 2020-04-30
EP3960196A1 (en) 2022-03-02
TWI740207B (zh) 2021-09-21
CA2905058A1 (en) 2014-09-25
US9611467B2 (en) 2017-04-04
US11185575B2 (en) 2021-11-30
SG10202001227QA (en) 2020-03-30
AU2018203665A1 (en) 2018-06-14
JP2016517421A (ja) 2016-06-16
NZ751610A (en) 2020-11-27
JP2023071821A (ja) 2023-05-23
KR20200041394A (ko) 2020-04-21

Similar Documents

Publication Publication Date Title
MX2021002513A (es) Composicion que comprende desintegrina y metaloproteinasa con motivos tipo i de trombospondina 13 (adamts13) para administracion subcutanea.
MX2023000320A (es) Metodos para modular los niveles de farmaco en plasma mediante el uso de eritrohidroxibupropion.
PH12018502731A1 (en) Treatment of cancer with dihydropyrazino-pyrazines
MX2016000364A (es) Metodos para tratar o prevenir afecciones oftalmologicas.
EP2702994A3 (en) Methods of administering pirfenidone therapy
MX2018004328A (es) Composiciones farmaceuticas estabilizantes de camptotecina.
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
WO2013149148A8 (en) Dosage forms of halofuginone and methods of use
MX2022007315A (es) Formulaciones de olanzapina de liberacion sostenida.
MX2014014814A (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
UA99921U (ru) Способ контролируемой седации у пациентов с состоянием отмены алкоголя в отделении интенсивной терапии
PH12015500178B1 (en) Injectable supersaturated acetaminophen solution for spinal administration
MX2016010919A (es) 4-bencilsulfonil-2-butenonitrilo.
UA99842U (ru) Способ проводниковой анестезии
MD4291C1 (ro) Preparat medicamentos pentru tratamentul otitelor
UA83813U (ru) Способ лечения нейросифилиса с мезенхимальными изменениями
UA89330U (uk) Спосіб профілактики розвитку запального синдрому відновлення імунітету у віл-інфікованих пацієнтів з токсоплазмозом головного мозку
IN2013MU03656A (es)
MX2012000360A (es) Combinacion de un atiinflamatorio no esteroideo y un antiespasmodico.